Shi-feng Kan

发表

TX‐1877, a bifunctional hypoxic cell radiosensitizer, enhances anticancer host response: Immune cell migration and nitric oxide production

H. Nagasawa, Y. Uto, H. Hori, 2005, International journal of cancer.

Sulforaphane regulates apoptosis- and proliferation-related signaling pathways and synergizes with cisplatin to suppress human ovarian cancer

Jian Wang, Shi-feng Kan, G. Sun, 2018, International journal of molecular medicine.

Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro.

M. Oka, S. Hazama, S. Homma, 2012, Anticancer research.

Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation

H. Tajiri, T. Ohkusa, Y. Namiki, 2013, Oncoimmunology.

Fusions between dendritic cells and whole tumor cells as anticancer vaccines

H. Arakawa, H. Tajiri, T. Ohkusa, 2013, Oncoimmunology.

Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent.

Mitsunobu Sato, M. Okamoto, T. Oshikawa, 2006, International immunopharmacology.

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Y. Kamata, K. Hayashi, S. Homma, 2015, BMC Cancer.

Growth of various obligate and facultative anaerobic intestinal bacteria in cell culture medium under aerobic and anaerobic culture conditions

T. Ohkusa, S. Koido, Shi-feng Kan, 2022, Bioscience of microbiota, food and health.

Impact of chemotherapy for colorectal cancer on regulatory T-cells and tumor immunity.

M. Oka, S. Hazama, K. Yoshimura, 2011, Anticancer research.

Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells.

T. Ohkusa, H. Sugiyama, S. Shimodaira, 2020, International journal of oncology.

Antitumor Effect of OK-432–Derived DNA: One of the Active Constituents of OK-432, a Streptococcal Immunotherapeutic Agent

S. Akira, Mitsunobu Sato, M. Okamoto, 2006, Journal of immunotherapy.

Mechanism of Anticancer Host Response Induced by OK-432, a Streptococcal Preparation, Mediated by Phagocytosis and Toll-Like Receptor 4 Signaling

K. Miyake, S. Akashi, S. Ahmed, 2006, Journal of immunotherapy.

Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells.

H. Arakawa, H. Tajiri, T. Ohkusa, 2014, International journal of oncology.

Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells.

H. Arakawa, H. Tajiri, T. Ohkusa, 2014, International journal of oncology.

Combined TLR2/4-Activated Dendritic/Tumor Cell Fusions Induce Augmented Cytotoxic T Lymphocytes

H. Arakawa, H. Tajiri, T. Ohkusa, 2013, PloS one.

Treatment with Chemotherapy and Dendritic Cells Pulsed with Multiple Wilms' Tumor 1 (WT1)–Specific MHC Class I/II–Restricted Epitopes for Pancreatic Cancer

T. Misawa, H. Arakawa, H. Tajiri, 2014, Clinical Cancer Research.

Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.

T. Misawa, H. Tajiri, T. Ohkusa, 2015, Anticancer research.

Anti-Tumor Effect of an Intratumoral Administration of Dendritic Cells in Combination with TS-1, an Oral Fluoropyrimidine Anti-Cancer Drug, and OK-432, a Streptococcal Immunopotentiator: Involvement of Toll-like Receptor 4

S. Ahmed, Mitsunobu Sato, M. Okamoto, 2004, Journal of immunotherapy.

Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma.

K. Nakashiro, H. Hamakawa, Y. Kawakami, 2013, Neoplasia.

Gemcitabine enhances rituximab‐mediated complement‐dependent cytotoxicity to B cell lymphoma by CD20 upregulation

Y. Kamata, K. Aiba, K. Hayashi, 2016, Cancer science.

The stimulatory effect of fusobacteria on dendritic cells under aerobic or anaerobic conditions

T. Ohkusa, M. Saruta, S. Koido, 2022, Scientific Reports.

Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines.

K. Nakashiro, H. Hamakawa, Y. Kawakami, 2012, Oral oncology.

Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.

H. Tajiri, T. Ohkusa, Y. Namiki, 2014, Anticancer research.

Augmentation of Antitumor Immunity by Fusions of Ethanol-Treated Tumor Cells and Dendritic Cells Stimulated via Dual TLRs through TGF-β1 Blockade and IL-12p70 Production

H. Arakawa, H. Tajiri, T. Ohkusa, 2013, PloS one.

Immunochemoradiotherapy for patients with oral squamous cell carcinoma: augmentation of OK-432-induced helper T cell 1 response by 5-FU and X-ray irradiation.

T. Bando, K. Nakashiro, H. Hamakawa, 2013, Neoplasia.

Production of corticotropin-releasing factor and urocortin from human monocyte-derived dendritic cells is stimulated by commensal bacteria in intestine.

H. Arakawa, H. Tajiri, T. Ohkusa, 2014, World journal of gastroenterology.

Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors.

Y. Kamata, K. Hayashi, S. Homma, 2015, Oncology reports.

Vaccination with vascular progenitor cells derived from induced pluripotent stem cells elicits antitumor immunity targeting vascular and tumor cells

Y. Kamata, K. Hayashi, S. Homma, 2014, Cancer Immunology, Immunotherapy.

Clinical Significance of Tumor-Infiltrating T Cells and Programed Death Ligand-1 in Patients with Pancreatic Cancer

T. Misawa, M. Saruta, H. Sugiyama, 2019, Cancer investigation.

Predicted Markers of Overall Survival in Pancreatic Cancer Patients Receiving Dendritic Cell Vaccinations Targeting WT1

T. Ohkusa, M. Saruta, H. Sugiyama, 2019, Oncology.

Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions

H. Arakawa, H. Tajiri, T. Ohkusa, 2013, Oncoimmunology.

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells

Y. Kamata, K. Hayashi, S. Homma, 2015, BMC Cancer.

Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.

Y. Kamata, K. Hayashi, S. Homma, 2015, Oncology reports.

MicroRNA-135 b is associated with tumor progression in colorectal cancer

Shi-feng Kan, G. Sun, Junsheng Yang, 2016 .

Targeting Human Poly(ADP‐Ribose) Polymerase‐1 with Natural Medicines and Its Potential Applications in Ovarian Cancer Therapeutics

Shi-feng Kan, Min Song, Xiao‐Ping Li, 2015, Archiv der Pharmazie.

Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma

T. Misawa, T. Ohkusa, M. Saruta, 2021, BMC Cancer.

Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.

Y. Kamata, K. Hayashi, S. Homma, 2015, Oncology reports.